Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Allimax International is a specialized health and nutraceutical company focused on the production and distribution of stabilized allicin, the primary bioactive component of garlic. The company utilizes a patented extraction process known as Allisure to produce the first fully stabilized allicin extract available for human consumption. Their product portfolio includes capsules, liquids, and topical formulations designed to support immune health and provide antimicrobial, antifungal, and antiviral benefits. Allimax International serves a global market, positioning its products as natural alternatives for managing various infections and cardiovascular health. The company's research-driven approach emphasizes the bioavailability of its stabilized allicin compared to traditional garlic supplements.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Allimax International.